Hyundai Bioscience
Financials
Valuation Metrics
Hyundai Bioscience's Market Cap is ₩5317B. At end of 2025 it was ₩4792B. Ranked #428 of 2,410 in KR market (top 18%), #154 of 1,631 on KOSDAQ (top 9%), #9 of 56 in Household & Personal Products (top 16%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 531.75B KRW | KR#428/2,410 Sec#9/56 |
| Revenue | 3.32B KRW | KR#2,355/2,410 Sec#56/56 |
| Net Income | -28.61B KRW | KR—/2,410 Sec—/56 |
| Total Assets | 131.31B KRW | KR#1,595/2,410 Sec#31/56 |
| Net Assets | 103.31B KRW | KR#1,390/2,410 Sec#28/56 |
| Employees | 55 | KR#2,006/2,410 Sec#49/56 |
| Value | ||
| P/B | 5.15x | KR#2,265/2,410 Sec#53/56 |
| P/S | 160.13x | KR#2,388/2,410 Sec#56/56 |
| FCF Yield | -3.28% | KR—/2,410 Sec—/56 |
| Profitability | ||
| ROE | -27.69% | KR#2,152/2,410 Sec#51/56 |
| ROA | -21.79% | KR#2,250/2,410 Sec#53/56 |
| Op. Margin | -580.09% | KR#2,359/2,410 Sec#56/56 |
| Revenue Growth | 77.96% | KR#125/2,410 Sec#3/56 |
| Financial Health | ||
| Debt Ratio | 27.10% | KR#523/2,410 Sec#15/56 |
| Total Debt | 21.32B KRW | KR#1,353/2,410 Sec#27/56 |
| FCF | -17.47B KRW | KR#1,855/2,410 Sec#46/56 |
| Cash | 17.08B KRW | KR#1,346/2,410 Sec#25/56 |
| Current Ratio | 2.36x | KR#728/2,410 Sec#22/56 |
| Performance | ||
| 1Y Return | 5.56% | KR#539/2,410 Sec#13/56 |
| 1M Return | -21.84% | KR#2,046/2,410 Sec#47/56 |
| From 52W High | -74.37% | KR#2,191/2,410 Sec#52/56 |
| 1Y MDD | -73.65% | KR#2,101/2,410 Sec#50/56 |
| Trading | ||
| Volume | 814,180 shares | KR#80/2,410 Sec#4/56 |
| Trading Value | 4.51B KRW | KR#298/2,410 Sec#9/56 |
| Foreign Own. | 6.24% | KR#708/2,410 Sec#14/56 |
| Per Share | ||
| EPS | -296 KRW | KR—/2,410 Sec—/56 |
| BPS | 1,070 KRW | KR#2,290/2,410 Sec#54/56 |
Company Info
Spun off from Hyundai Electronics in 2000, this bio pharmaceutical and cosmeceutical company was listed on KOSDAQ in 2002 and renamed Hyundai Bioscience in 2018. It is developing the broad-spectrum antiviral treatment CP-COV03 and anticancer drugs Polytaxel and Penicillium, while expanding its domestic and international markets with high-functional cosmetics Vitabrid C12 (exported to Japan) and Dr.BRID C. The company is securing new drug development pipelines in cooperation with C&Pharm and pursuing commercialization of clinical results through exchanges with international organizations. Hyundai Bio is headquartered in Gimcheon-si, Gyeongsangbuk-do.